CLINICAL ROUNDTABLE #2: Medications Development for Cannabis Use Disorder: CB1 Receptor Agonists, Antagonists and Signaling-Specific Inhibitors
Margaret Haney, PhD
Date & Time: Tuesday, November 15, 2016 8:30am - 11am
Panelists: Zuzana Justinova, MD, PhD; Pier Vincenzo Piazza, MD, PhD; Jack Bergman, PhD
Treatment outcome for cannabis use disorder is poor and is limited by a lack of efficacious medications. This symposium will discuss the latest preclinical and clinical studies testing potential treatment medications targeting the cannabinoid receptor (CB1) for the treatment of CUD. Specifically, the effects of CB1 agonists, inverse agonists, orthosteric antagonists, signaling-specific inhibitors and endocannabinoid enzyme inhibitors in models of drug discrimination, self-administration, withdrawal and reinstatement will be described.